• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

COVID-19大流行期间多发性骨髓瘤的管理

Management of multiple myeloma during COVID-19 pandemic.

作者信息

Jethava Y S, Fonseca Rafael, Landgren Ola

机构信息

Division of Hematology and Cellular Therapy, University of Iowa Hospitals and Clinics, 200 Hawkins Dr, 5970 JPP, Iowa City, IA 52242, United States.

Interim Executive Director, Mayo Clinic Comprehensive Cancer Center, Director for Innovation and Transformational Relationships, Getz Family Professor of Cancer, Distinguished Mayo Investigator, 5777 East Mayo Boulevard, Phoenix, AZ 85054, United States.

出版信息

Leuk Res Rep. 2020 Jun 13;14:100212. doi: 10.1016/j.lrr.2020.100212. eCollection 2020.

DOI:10.1016/j.lrr.2020.100212
PMID:32704473
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7293439/
Abstract

At the end of 2019, a novel coronavirus was identified as the cause of pneumonia cases in Wuhan, a city in the Hubei Province of China. On January 30, 2020, the World Health Organization (WHO) declared the COVID-19 outbreak a public health emergency of international concern and, in March 2020, began to characterize it as a pandemic. The virus that causes COVID-19 is designated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) In February 2020, the World Health Organization designated the disease COVID-19, which stands for coronavirus disease 2019.

摘要

2019年底,一种新型冠状病毒被确认为中国湖北省武汉市肺炎病例的病因。2020年1月30日,世界卫生组织(WHO)宣布新冠疫情为国际关注的突发公共卫生事件,并于2020年3月开始将其定性为大流行病。引起新冠疫情的病毒被命名为严重急性呼吸综合征冠状病毒2(SARS-CoV-2)。2020年2月,世界卫生组织将该疾病命名为COVID-19,即2019冠状病毒病。

相似文献

1
Management of multiple myeloma during COVID-19 pandemic.COVID-19大流行期间多发性骨髓瘤的管理
Leuk Res Rep. 2020 Jun 13;14:100212. doi: 10.1016/j.lrr.2020.100212. eCollection 2020.
2
Correlation between the migration scale index and the number of new confirmed coronavirus disease 2019 cases in China.中国新型冠状病毒病新增确诊病例数与迁移规模指数的相关性。
Epidemiol Infect. 2020 May 19;148:e99. doi: 10.1017/S0950268820001119.
3
Solidarity in response to COVID-19 outbreak in the Eastern Mediterranean Region.团结一致应对东地中海区域的 COVID-19 疫情。
East Mediterr Health J. 2020 May 21;26(5):492-494. doi: 10.26719/2020.26.5.492.
4
The spatial transmission of SARS-CoV-2 in China under the prevention and control measures at the early outbreak.疫情初期防控措施下新型冠状病毒在中国的空间传播。
Arch Public Health. 2021 Jan 13;79(1):8. doi: 10.1186/s13690-021-00529-z.
5
COVID-19-A Novel Zoonotic Disease: A Review of the Disease, the Virus, and Public Health Measures.COVID-19 新型人畜共患病:疾病、病毒和公共卫生措施综述。
Asia Pac J Public Health. 2020 May;32(4):145-153. doi: 10.1177/1010539520931326. Epub 2020 May 30.
6
Corona Viruses: A Review on SARS, MERS and COVID-19.冠状病毒:关于严重急性呼吸综合征、中东呼吸综合征和新型冠状病毒肺炎的综述。
Microbiol Insights. 2021 Mar 19;14:11786361211002481. doi: 10.1177/11786361211002481. eCollection 2021.
7
Laboratory diagnosis of severe acute respiratory syndrome coronavirus 2.严重急性呼吸综合征冠状病毒 2 的实验室诊断。
Pathology. 2020 Dec;52(7):745-753. doi: 10.1016/j.pathol.2020.09.011. Epub 2020 Oct 8.
8
A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group.新型冠状病毒病 2019(COVID-19)大流行期间癌症患者管理的实用方法:国际协作组。
Oncologist. 2020 Jun;25(6):e936-e945. doi: 10.1634/theoncologist.2020-0213. Epub 2020 Apr 27.
9
Coronavirus disease 2019: A new severe acute respiratory syndrome from Wuhan in China.2019冠状病毒病:一种源自中国武汉的新型严重急性呼吸综合征。
Acta Virol. 2020;64(2):245-250. doi: 10.4149/av_2020_201.
10
Response to Covid-19: An ethical imperative to build a resilient health system in India.对新冠疫情的应对:在印度建立具有韧性的卫生系统的道德要求。
Indian J Med Ethics. 2020 Apr-Jun;V(2):1-4. doi: 10.20529/IJME.2020.026.

引用本文的文献

1
Clinical Features and Risk Stratification of Multiple Myeloma Patients with COVID-19.新型冠状病毒肺炎(COVID-19)多发性骨髓瘤患者的临床特征及风险分层
Cancers (Basel). 2023 Jul 13;15(14):3598. doi: 10.3390/cancers15143598.
2
Virtual care for multiple myeloma in the COVID-19 era: interrupted time series analysis of veterans health administration data.COVID-19 时代多发性骨髓瘤的虚拟护理:退伍军人健康管理数据的中断时间序列分析
Leuk Lymphoma. 2023 May;64(5):1035-1039. doi: 10.1080/10428194.2023.2189989. Epub 2023 Mar 16.
3
Prolonged Lenalidomide Induction Does Not Significantly Impair Stem Cell Collection in Multiple Myeloma Patients Mobilized With Cyclophosphamide or Plerixafor: A Report From The Covid Era.在新冠肺炎时代,与环磷酰胺或普乐沙福联合应用时,来那度胺诱导时间延长并不会显著影响多发性骨髓瘤患者干细胞采集。
Clin Lymphoma Myeloma Leuk. 2022 Aug;22(8):e716-e729. doi: 10.1016/j.clml.2022.03.013. Epub 2022 Mar 28.
4
Canadian perspective on managing multiple myeloma during the COVID-19 pandemic: lessons learned and future considerations.加拿大在 COVID-19 大流行期间管理多发性骨髓瘤的观点:经验教训和未来考虑。
Curr Oncol. 2020 Oct;27(5):270-274. doi: 10.3747/co.27.7149. Epub 2020 Oct 1.

本文引用的文献

1
Compassionate Use of Remdesivir for Patients with Severe Covid-19.瑞德西韦在治疗重症 COVID-19 患者中的同情使用。
N Engl J Med. 2020 Jun 11;382(24):2327-2336. doi: 10.1056/NEJMoa2007016. Epub 2020 Apr 10.
2
First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab.首例多发性骨髓瘤合并 COVID-19 患者经托珠单抗治疗后成功缓解。
Blood Adv. 2020 Apr 14;4(7):1307-1310. doi: 10.1182/bloodadvances.2020001907.
3
Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China.COVID-19 感染癌症患者的临床特征:中国武汉三家医院的回顾性病例研究。
Ann Oncol. 2020 Jul;31(7):894-901. doi: 10.1016/j.annonc.2020.03.296. Epub 2020 Mar 26.
4
Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020.2020 年 2 月 12 日至 3 月 16 日,美国 2019 冠状病毒病(COVID-19)患者的严重结局。
MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):343-346. doi: 10.15585/mmwr.mm6912e2.
5
Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China.新冠肺炎住院患者中心脏损伤与死亡的相关性研究:中国武汉。
JAMA Cardiol. 2020 Jul 1;5(7):802-810. doi: 10.1001/jamacardio.2020.0950.
6
Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy.意大利新冠肺炎死亡患者的病死率及特征
JAMA. 2020 May 12;323(18):1775-1776. doi: 10.1001/jama.2020.4683.
7
Viral dynamics in mild and severe cases of COVID-19.新冠肺炎轻症和重症病例中的病毒动力学
Lancet Infect Dis. 2020 Jun;20(6):656-657. doi: 10.1016/S1473-3099(20)30232-2. Epub 2020 Mar 19.
8
COVID-19: consider cytokine storm syndromes and immunosuppression.2019冠状病毒病:考虑细胞因子风暴综合征和免疫抑制。
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
9
Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State.华盛顿州 21 例 COVID-19 危重症患者的特征和结局。
JAMA. 2020 Apr 28;323(16):1612-1614. doi: 10.1001/jama.2020.4326.
10
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素:一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.